Kornimate/medical-research-clean huggingface dataset:
the effects of metformin on self-selected exercise intensity, physical fitness and exercise-induced ampk-activation

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate the potential interaction between metformin and exercise in order to optimize clinical guidelines for treatment of t2d.

physical activity is a first line treatment for patients with type 2 diabetes (t2d ), however, the vast majority of patients with t2d do not achieve satisfying glycemic control with physical activity alone, which is why pharmacological treatment with metformin is most often initiated. it is known that metformin and exercise both activates ampk, which results in many different metabolic effects. because of this similarity, an interaction between metformin and exercise is plausible, but knowledge in the area is sparse. with this study the investigators aim to look at the individual and combined effects of metformin and exercise in order to investigate whether an interaction occur. an interaction will have tremendous clinical importance for patients with t2d given current guidelines where the vast majority of these patients are recommended both exercise and metformin treatment. the investigators hypothesize that metformin treatment reduces self-selected exercise intensity, which may be explained via decreased mitochondrial complex 1 function, increased blood lactate levels, heart rate and rpe during exercise. furthermore exercise-induced ampk-activation is reduced with metformin treatment.

Eligibility criteria:
inclusion criteria: * male * hba1c \< 39 mmol/l * bmi \< 25 * structured physical activity \< = 150 min/week * apparently healthy exclusion criteria: * smoking * daily pharmaceutical treatment * contraindication to increased levels of physical activity * alat/asat elevated 3 times above upper normal values * renal insufficiency (egfr \< 60 ml/min) * prior history of lactic acidosis
developing a non-contact sleep apnoea detector, suitable for home studies- the safescan study

Conditions: Sleep Apnoea; Obstructive Sleep Apnoea

Summary: sleep apnoea (sa) is a common condition in adults and children that causes disturbed sleep and daytime symptoms. it is characterised by disrupted breathing with disturbed sleep patterns. in adults this can lead to dangerous daytime sleepiness affecting for example driving performance. in children it may lead to hyperactivity in the day and poor school performance. there are a number of techniques for diagnosing the disorder but they can affect the quality of sleep which sometimes makes them inaccurate. most are unsuitable for small children who cannot understand the value of the tests and tend to remove the monitoring wires and devices in the night. this study aims to validate a new non contact device "safescan", based on low power radar technology, which can be put under a bed and record breathing patterns with no measuring device in contact with the sleeper. in this initial study the device will be validated in adults, against the gold standard of polysomnography (psg) in the sleep laboratory at royal papworth hospital.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * able to give informed consent exclusion criteria: * patient with known sleep disordered breathing using a treatment device (e.g. continuous positive airway pressure) on the night of the study. * polysomnography study records less than 4 hours of respiratory data
ambulatory laparoscopic sleeve gastrectomy

Conditions: Obesity, Morbid

Summary: in the era of laparoscopic surgery, day case procedures are increasingly practiced around the world, however, day case bariatric surgery remains a controversial issue due to lack of sufficient evidence evaluating its safety. laparoscopic sleeve gastrectomy (lsg) is currently the most popular bariatric surgery performed worldwide, and the standard is 1-2 days postop stay. however, the american college of surgeons and the american society for metabolic and bariatric surgery released guidelines in 2016 that allowed lsg in ambulatory surgery centers for low acuity patients. in the present trial, investigators will compare the safety and feasibility of same day discharge vs next day discharge in a large group of patients undergoing laparoscopic sleeve gastrectomy.

this is a 2-group, randomized, open label clinical trial patients who will be recruited at an asc to undergo lsg with same-day discharge, termed ambulatory surgery center lsg (asc lsg) or lsg with conventional hospitalization and next day discharge (ch lsg). the study will recruit participants between december 2018 and december 2020. data collected will include including age, body mass index (bmi), operative time, recovery room time, hospital stay, readmission, follow up visits, asc visits, adverse events, and re-operation rates.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 65 years 2. body mass index \<60 3. american anesthesiologists association classification ≤iii 4. commitment to stay within close proximity to the ambulatory surgery center for 4 days after surgery exclusion criteria: 1. high risk for thromboembolic disease 2. has a history of major open abdominal surgery 3. bleeding disorders 4. heart disease 5. pulmonary hypertension 6. uncontrolled type 2 diabetes 7. severe obstructive sleep apnea 8. chronic obstructive pulmonary disease

Keywords: sleeve gastrectomy ambulatory surgery day case surgery
the influence of education during waiting time of vaccination on the knowledge towards covid-19 among chinese residents

Conditions: Covid19; Knowledge, Attitudes, Practice

Summary: coronavirus disease 2019 (covid-19) is a respiratory disease caused by a novel coronavirus, which has developed the global pandemic situation. the promotion of vaccination is an effective strategy to control the epidemic. a total of 19,5738,000 doses of covid-19 vaccines have been reported in china until august 24th, 2021. during widespread vaccination, the education in covid-19 prevention and vaccination for residents are also crucial. to figure out the influence of education during waiting time of vaccination, we have designed a randomized controlled trial and planned to distribute leaflets and questionnaires to the residents of xidian (a town in ninghai, zhejiang). this study is of great significance for the prevention of covid-19 pandemic.


Eligibility criteria:
inclusion criteria: 1. age ≥18; 2. residents who are vaccinated with covid-19 vaccines at xidian passenger station from august 18th to september 20th, 2021; 3. able to understand the content of leaflets and questionnaires, and willing to participate in the study. exclusion criteria: 1. residents who are unable to get vaccinated with covid-19 vaccines; 2. unable to understand the content of leaflets and questionnaires, or unwilling to participate in the study; 3. unreturned or incomplete questionnaires.
safety and efficacy of av608 in subjects with idiopathic detrusor overactivity

Conditions: Overactive Bladder Syndrome

Summary: the purpose of this study is to assess the effects of av608, a neurokinin 1 (nk-1) antagonist, in subjects with idiopathic detrusor overactivity.

this is a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of av608 in subjects with idiopathic detrusor overactivity. female subjects between 18 and 65 years of age with a diagnosis of overactive bladder syndrome and urodynamic observation of involuntary detrusor contractions during the filling phase will be eligible for the trial. eligible subjects will complete a baseline urodynamic assessment. all subjects who participate in the study will receive 3 weeks of treatment with av608 or placebo. at the end of the treatment period, subjects will complete a second urodynamic assessment.

Eligibility criteria:
inclusion criteria: * female, 18 to 65 years of age, inclusive * a current primary diagnosis of oab * idiopathic detrusor overactivity, demonstrated by a urodynamic observation * evidence of frequency in combination with urinary urgency * written informed consent form * willingness to avoid pregnancy and practice adequate birth control * negative serum pregnancy test * agrees to refrain from blood donation during the course of the study exclusion criteria: * subjects who are pregnant or lactating * clinically significant abnormality or clinically significant unstable medical condition * qtc interval of 470 msec or greater at visit 1 * predominant stress urinary incontinence versus urge urinary incontinence based on subject history * neurogenic bladder (e.g. associated with spinal cord injury, multiple sclerosis, etc.) * anatomic or structural abnormalities possibly causing urinary incontinence or urgency, including but not limited to urogenital prolapse stage 2 or more according to the pelvic organ prolapse quantification (pop-q) system * urological or gynecological surgery within 3 months of the baseline urodynamic assessment * current uti or frequent utis (i.e., greater than or equal to 4 utis per year), interstitial cystitis, hematuria of unknown cause, or use of indwelling catheter * electro-stimulation therapy, bladder training, or physiotherapy for bladder control within 2 weeks of visit 1 * history (within 1 year of screening) of alcohol or substance dependence (except nicotine dependence) according to dsm-iv-tr criteria * history of any kind of cancer within the last 2 years * existing non-malignant tumors that could compromise the function and/or anatomy of the lower urinary tract

Keywords: idiopathic detrusor overactivity nk-1 receptor antagonist neurokinin urge incontinence
trial of indomethacin in chronic pancreatitis

Conditions: Chronic Pancreatitis

Summary: the researchers are trying to find a way to slow down the progression of chronic pancreatitis (cp) and investigate the possibility of the long term treatment of this disease.


Eligibility criteria:
inclusion criteria: 1. any gender, age ≥ 18 years and \< 60 years 2. diagnosed with chronic pancreatitis per american pancreatic association guidelines (pancreatic calcifications and/or cambridge 3-4 changes on ct, mri, and/or ercp) 3. scheduled for an upper gi endoscopic procedure (egd or eus) for clinical or research) indications (not conflicting with current investigation). 4. able to provide written informed consent. 5. serum creatinine within normal laboratory range, as measured within 30 days of the baseline study endoscopy. 6. for females of reproductive potential: willing to use highly effective contraception while taking study medication and for an additional 5 days after completing study medication. exclusion criteria: 1. diagnosed with acute pancreatitis requiring hospitalization within the 6 weeks prior to study enrollment. 2. habitual use of aspirin or non-steroidal anti-inflammatory medications (nsaids), defined as use more than once per week. 3. any use of aspirin or nsaids within 1 week of baseline study endoscopy procedure. 4. allergy to secretin, indomethacin or nsaids. 5. history of known chronic renal insufficiency or cirrhosis. 6. history of coronary artery disease, angina pectoris, myocardial infarction, cerebrovascular accident (stroke), or transient ischemic accident (tia). 7. history of peptic ulcer or gastrointestinal bleeding. 8. incarcerated. 9. found to have active gi ulceration at the time of baseline endoscopy. 10. hospitalized for acute pancreatitis while participating in this research protocol. participants who are hospitalized for an episode of acute pancreatitis during study participation will be withdrawn from the study, and considered non-accrued.
fat effects in women with metabolic syndrome

Conditions: Metabolic Syndrome

Summary: among 10 premenopausal women with metabolic syndrome: specific aim 1: compare the effects of acute fat feeding on flow mediated dilation (fmd) as measured by brachial artery reactivity among three fat challenges (saturated fat vs. monounsaturated fat (mufa) vs. polyunsaturated fat (pufa)at 4 hours post feeding. hypothesis saturated fat feeding will impair fmd but mufa and pufa feeding will not. specific aim 2: compare the effects of acute feeding on vascular inflammation as measured by vcam and sicam among three fat challenges at 3 1/2 hours post feeding. hypothesis: saturated fat feeding will increase vascular inflammation but mufa and pufa will not.


Eligibility criteria:
inclusion criteria: * female, * 18-50 years of age, * pre-menopausal, * weight stable for at least 3 months, * not planning to lose or gain weight for 3 months, * meets the following 3/5 criteria for metabolic syndrome: * increased blood sugar * increased blood fats (triglycerides), * increased blood pressure, * decreased good cholesterol (hdl-c). * increased waist circumference, exclusion criteria: * history of diabetes mellitus * fasting glucose ≥ 126 mg/dl * history of cardiovascular disease (peripheral vascular disease, coronary artery disease, cerebrovascular disease) * pregnant or planning a pregnancy within the study period * fasting triglycerides \> 500 mg/dl * currently taking lipid lowering medications\*\* * oral or patch hormone contraception\*\* * currently taking vaso-active (blood pressure) medications\*\* * sbp ≥ 140 and/or dbp ≥90 mm hg or taking blood pressure lowering rx * chronic use of aspirin (prn use is allowed) * chronic use of non-steroidal anti-inflammatory medications (prn use is allowed) * tobacco use within 6 months of starting study * participation in another clinical trial within the last 30 days * history of active gall bladder disease * history of digestive or malabsorptive disease requiring treatment or surgery * moderate to severe lactose intolerance * milk allergy * walnut allergy or nut allergy * coconut allergy (\*\*) drugs within the following classifications are exclusionary: lipid lowering, beta blockers, ace inhibitors, angiotensin receptor blockers, diuretics, calcium channel blockers, alpha blockers, nitrates, hormone contraception includes patch or oral hormone contraception (hormone containing iuds or vaginal rings are okay)

Keywords: metabolic syndrome premenopausal women fat feeding
home monitoring vs. hospitalization for mild acute pancreatitis

Conditions: Acute Pancreatitis

Summary: acute pancreatitis accounts for a large number of hospital admissions every year. some studies have shown that early oral feeding protocols are safe, and one previous study suggests the possibility of home care for mild acute pancreatitis.

approximately 80% of all cases of acute pancreatitis are mild and only require supportive care for pain and nausea control and an adequate fluid replacement. currently, all patients in our setting diagnosed with mild acute pancreatitis are admitted to a conventional hospitalization ward under the supervision of the digestive and general surgery department or the gastroenterology department. symptomatic treatment is administered, and abdominal ultrasound is performed to assess the cause of pancreatic inflammation. the remaining 20% fulfill the severity criteria from its onset onwards and require intensive care support. we will conduct a multicenter randomized controlled clinical trial to compare two different approaches to mild non-alcoholic acute pancreatitis: hospital admission and outpatient management.

Eligibility criteria:
inclusion criteria patients diagnosed with mild acute pancreatitis based on at least two of the three following criteria: * abdominal pain * amylase or lipase 3x uln (in blood/urine) * imaging tests (ultrasound/ct scan) suggestive of acute pancreatitis. age ≥18 years and \<80 years absence of potential pancreatitis-related severity criteria: * no evidence of sirs in the emergency room * c-reactive protein levels \<150mg/dl * marked increase in the white blood cell count * absence of coagulopathy (inr \<1.4) * hematocrit \< 44% * creatinine \< 170 µmol/l * bisap score ≤2 at the time of randomization. patients with good pain response to 12-hour supportive care in the er (vas \<4) or adequate oral feeding tolerability. absence of local or systemic complications of acute pancreatitis on imaging tests. adequate cognitive capacity and without any previous diagnose of psychiatric disease. patients who meet each participating hospital home care criteria. patients who give their written informed consent to participate. exclusion criteria past medical history of pancreatic disease: * known or newly diagnosed chronic pancreatitis (wirsung dilation or pancreatic calcifications in previous imaging tests) * patients with recurrent acute pancreatitis (\>3 episodes/year) or an episode of acute pancreatitis \<1 month ago. * acute pancreatitis after endoscopic retrograde cholangiography. * hyperbilirubinemia \>3x uln comorbidities that required previous hospitalization (myocardial infarction, liver cirrhosis, chronic kidney disease, or chronic lung disease). bmi ≥35 kg/m2 patients who refuse to participate in the study.

Keywords: acute pancreatitis mild pancreatitis outpatient protocol
analysis of orthopedic patients response to new pain modulating substances and drugs

Conditions: Low Back Pain

Summary: data of patient reported outcomes (pro) are collected during treatment with various pain alleviation methods (drugs or substances)

the study aims at collecting bpi (brief pain inventory) and other pro of patients in need of pain relief due to chronic orthopedic pain conditions

Eligibility criteria:
inclusion criteria: chronic pain of orthopedic origin treated for at least one year unsuccessfully exclusion criteria: contra-indication for cannabis treatment
bbc one - british bifurcation coronary study

Conditions: Ischaemic Heart Diseases; Stenosis; Angina

Summary: the study aims to assess whether a simple or a complex strategy is best for the treatment of coronary bifurcation stenoses.

500 patients will be randomised to either a simple strategy (provisional t stenting) or a complex strategy (crush or culotte stenting) with clinical follow-up at 9 months.

Eligibility criteria:
inclusion criteria:\>18 years * coronary bifurcation lesion requiring treatment exclusion criteria: * cardiogenic shock * acute mi * additional type c lesion for rx platelets \<50 * lvef \<20%

Keywords: bifurcation coronary stenosis stent drug elution
evaluating glial acetate metabolism as a biomarker of hypoglycemic complications in diabetic patients

Conditions: Diabetes; Hypoglycemia

Summary: a recent pilot study, glimpse (nct02690168), was recently completed which demonstrated that the rate of glial acetate metabolism (gam) is closely associated with susceptibility to fasting-induced hypoglycemia in healthy adults. insulin-induced hypoglycemia is a common complication of diabetes treatment and is a major barrier to the maintenance of healthy glucose levels in individuals with diabetes. the primary purpose of the study is to test the proof-of-concept that there is an association between the rate of gam and susceptibility to insulin-induced hypoglycemia. in order to observe such a relationship the rate of gam will be measured in a patient population known to frequently experience hypoglycemia, i.e., individuals with type 1 diabetes mellitus (t1dm).


Eligibility criteria:
inclusion criteria: * male or female * ages 18-40 years * diagnosed with type 1 diabetes with positive antibodies or dependent on insulin therapy * hba1c of ≤8.5% * modified clarke's hypoglycemia questionnaire score of 12-24 * willing to participate in continuous glucose monitoring (cgm) exclusion criteria: * contraindication to mri * consume \>10 alcoholic drinks/week * current use of cgm * current use of insulin pump * current use of any diabetes medication other than insulin, e.g. sglt1/2 inhibitors. * current use of steroids, e.g. cortisone, and prednisone. * history of chronic smoking or have quit less than 10 years ago * history of cancer in the past 5 years (individuals with basal cell or squamous cell skin cancer would be allowed) * history of seizures * significant, cardiac, vascular, pulmonary, gastrointestinal, neurologic, hematologic, rheumatologic, or psychiatric disease * significant liver disease as defined as more than twice the upper limit of normal for liver enzymes * significant renal disease as defined as a estimated glomerular filtration rate less than 30 * pregnant, planning to become pregnant, or breastfeeding * have been hospitalized or treated in the past 3 months for severe hypoglycemia * based on the investigative team's clinical judgement, a subject may not be appropriate for participation in the study.
aspirin effectiveness study

Conditions: Coronary Artery Disease

Summary: aspirin is an effective medicine for prevention of heart attacks in patients with coronary artery disease and works by preventing clots from forming. in previous studies aspirin has been found to be ineffective in between 2% and 65% of patients but none of these studies have looked specifically at coronary artery disease patients in ireland. this study is being done to identify the percentage of patients in ireland whose aspirin is not working effectively and help identify factors that could be used to target interventions to increase aspirin's effectiveness in irish patients.


Eligibility criteria:
inclusion criteria: * age 18 years or older * patients with documented coronary artery disease * current treatment with any dose of aspirin daily for a minimum of 3 months * able to provide written informed consent based on competent mental status exclusion criteria: * myocardial infarction, unstable angina or stroke during the preceding three months * platelet count \<125,000/mm * known haematological disorders * active malignancy on current chemotherapy or a recent diagnosis of cancer

Keywords: coronary artery disease aspirin secondary prevention
effect of intravenous dextrose on ponv in patients undergoing gynecological laparoscopy

Conditions: Postoperative Nausea and Vomiting

Summary: this study is to explore the relationship between intravenous infusion of dextrose during emergence from anesthesia and the incidence of ponv in patients undergoing gynecology laparoscopy (gl).


Eligibility criteria:
inclusion criteria: 1. asa i or ii; 2. performing gynecologic laparoscopic procedures under general anesthesia; exclusion criteria: 1. age \ 75 2. severe hypertension,diabetes mellitus, significant hepatic or renal disease 3. inability to follow protocol 4. refusal to participant

Keywords: ponv